Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920764 · ClinicalTrials.gov registry record · Phase 2
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT00920764 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 92 participants.
The verdict
NCT00920764, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
The study objective is to investigate the effects of three low doses of atrasentan on urinary albumin/creatinine ratio (UACR) levels in subjects with Type 2 diabetic nephropathy. Patients with Type 2 diabetes with nephropathy must be receiving a renin-angiotensin system inhibitor, such as an Angiotensin converting enzyme inhibitor (ACEi) or an Angiotensin II Receptor Blocker (ARB) for participation in this study. ACEi and ARB treatment are the standard of care for the management of proteinuria in Chronic Kidney Disease (CKD) patients.
Interventions
- DRUG Placebo for Atrasentan 0.2 mg/mL solution
- DRUG 0.25 mg Atrasentan QD
- DRUG 0.75 mg Atrasentan QD
- DRUG 1.75 mg Atrasentan QD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00920764
The ClinicalTrials.gov registry entry for NCT00920764 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo for Atrasentan 0.2 mg/mL solution is the first listed.
NCT00920764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00920764 about?
NCT00920764 is a clinical study titled "A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors". The study objective is to investigate the effects of three low doses of atrasentan on urinary albumin/creatinine ratio (UACR) levels in subjects with Type 2 diabetic nephropathy. Patients with Type 2 diabetes with nephropathy must be receiving a renin-angiotensin system inhibitor, such as an Angiot...
What is the current status of trial NCT00920764?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2009-06. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00920764?
The interventions under investigation include: Placebo for Atrasentan 0.2 mg/mL solution (DRUG), 0.25 mg Atrasentan QD (DRUG), 0.75 mg Atrasentan QD (DRUG), 1.75 mg Atrasentan QD (DRUG).
Who is sponsoring clinical trial NCT00920764?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.